• 1. A comprehensive review of glycosylated bacterial natural products
  Sherif I. Elshahawi,Khaled A. Shaaban,Madan K. Kharel,Jon S. Thorson Chem. Soc. Rev. 2015 44 7591
• 2. Hot off the Press
  Robert A. Hill,Andrew Sutherland Nat. Prod. Rep. 2016 33 742
• 3. Nitrile-containing natural products
  Fraser F. Fleming Nat. Prod. Rep. 1999 16 597
• 4. Synthesis and absolute configuration of the naturally occurring cyano glucoside simmondsin
  Noritaka Chida,Ken Yamada,Seiichiro Ogawa J. Chem. Soc. Perkin Trans. 1 1992 1131

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds O-glycosyl compounds
• Natural Products and Extracts Plant Extracts Plant based Miscellaneous

Professional Introduction to Menisdaurin (CAS No: 67765-58-6)

Menisdaurin, a naturally occurring phytochemical, has garnered significant attention in the field of chemical biomedicine due to its remarkable pharmacological properties. With a CAS number of 67765-58-6, this compound has been extensively studied for its potential therapeutic applications. The structural complexity and unique biological activities of Menisdaurin make it a subject of intense research, particularly in the context of antioxidant, anti-inflammatory, and anticancer mechanisms.

The chemical structure of Menisdaurin consists of a polyphenolic framework, which is characteristic of many bioactive natural products. This structure contributes to its ability to interact with various biological targets, including enzymes and receptors involved in cellular signaling pathways. Recent studies have highlighted the compound's potent free radical scavenging capabilities, making it a promising candidate for applications in neuroprotection and cardiovascular health.

In the realm of cancer research, Menisdaurin has been shown to exhibit significant inhibitory effects on the proliferation of several cancer cell lines. Its mechanism of action involves the modulation of key signaling pathways such as the PI3K/Akt and NF-κB pathways, which are often dysregulated in malignant tumors. Furthermore, preclinical studies have demonstrated that Menisdaurin can induce apoptosis in cancer cells while sparing healthy cells, suggesting its potential as a selective anticancer agent.

The anti-inflammatory properties of Menisdaurin have also been extensively investigated. Research indicates that the compound can suppress the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 by inhibiting key inflammatory enzymes like COX-2 and iNOS. These findings position Menisdaurin as a valuable candidate for the development of novel therapeutics for chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

One of the most compelling aspects of Menisdaurin is its ability to cross the blood-brain barrier, which has opened up new avenues for its application in central nervous system disorders. Studies have shown that Menisdaurin can protect against neurodegenerative diseases such as Alzheimer's and Parkinson's by mitigating oxidative stress and inhibiting the aggregation of amyloid-beta plaques. These findings are particularly exciting given the growing burden of neurodegenerative disorders worldwide.

The synthesis and purification of Menisdaurin have also been subjects of considerable interest. Researchers have developed efficient synthetic routes that allow for the scalable production of this compound, which is crucial for both preclinical and clinical studies. Additionally, advancements in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry have enabled researchers to accurately determine the purity and chemical profile of Menisdaurin samples.

The pharmacokinetic properties of Menisdaurin have been carefully evaluated to understand its absorption, distribution, metabolism, and excretion (ADME) profiles. Studies have revealed that Menisdaurin exhibits moderate oral bioavailability and a favorable half-life, suggesting its potential for therapeutic use. Furthermore, preliminary toxicology studies have shown that Menisdaurin is well-tolerated at doses relevant to its intended therapeutic applications.

As research into Menisdaurin continues to evolve, new applications are being discovered that further underscore its significance in chemical biomedicine. For instance, recent studies have explored its potential role in modulating immune responses, making it a candidate for immunotherapy approaches against cancer and infectious diseases. The multifaceted biological activities of Menisdaurin make it a versatile compound with broad therapeutic implications.

In conclusion, Menisdaurin (CAS No: 67765-58-6) represents a fascinating example of how natural products can serve as leads for novel therapeutics. Its unique chemical structure and diverse biological activities position it as a promising candidate for treating a wide range of diseases, from cancer to neurodegenerative disorders. As research progresses, it is likely that additional applications for this remarkable compound will be uncovered, further solidifying its importance in the field of chemical biomedicine.

• 165306-60-5(b-D-Glucopyranoside,2-hydroxy-4-(3-hydroxy-1-butenyl)-3,5,5-trimethyl-3-cyclohexen-1-yl (9CI))
• 162990-70-7(Acetonitrile,[(4S,6S)-6-(b-D-glucopyranosyloxy)-4-hydroxy-2-cyclohexen-1-ylidene]-,(2Z)-)
• 165133-73-3(β-D-Glucopyranoside, (1R,6S)-6-hydroxy-3-[(1E,3R)-3-hydroxy-1-buten-1-yl]-2,4,4-trimethyl-2-cyclohexen-1-yl)
• 126005-76-3(β-D-Glucopyranoside, (1S,2R)-2-hydroxy-4-[(1E,3R)-3-hydroxy-1-buten-1-yl]-3,5,5-trimethyl-3-cyclohexen-1-yl)
• 84799-31-5(5-Epilithospermoside)
• 100757-58-2(Acetonitrile,[(4R,5S,6S)-6-(b-D-glucopyranosyloxy)-5-hydroxy-4-methoxy-2-cyclohexen-1-ylidene]-,(2Z)- (9CI))
• 146610-77-7((7E,9ξ)-5,7-Megastigmadien-9-ol)
• 63492-69-3(Lithospermoside)
• 51771-52-9(Simmondsin)
• 72523-59-2((2Z)-[(4S,5S,6S)-6-(beta-D-glucopyranosyloxy)-4,5-dihydroxycyclohex-2-en-1-ylidene]ethanenitrile)